Three opportunities continue in the market, with little else looking particularly well priced for a value play of the kind that I seek out with high cash flow and something of a dividend to pay for your patience.  Exelon, France Telecom and Abbott Labs have all been acquisition targets, and if you bought them earlier you are seeing the float upward with the market right now, with a small spike for Exelon’s merger news.

Read the rest of this entry »